{
    "clinical_study": {
        "@rank": "11805", 
        "arm_group": [
            {
                "arm_group_label": "Fimasartan and Amlodipine", 
                "arm_group_type": "Experimental", 
                "description": "Combination of Fimasartan and Amlodipine"
            }, 
            {
                "arm_group_label": "Fimasartan", 
                "arm_group_type": "Active Comparator", 
                "description": "Fimasartan Monotherapy"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in\n      hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with\n      hypertension who have no response to Fimasartan 60mg monotherapy."
        }, 
        "brief_title": "Fimasartan/Amlodipine Combination Phase III", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Essential Hypertension", 
        "condition_browse": {
            "mesh_term": "Hypertension"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subjects who voluntarily signed informed consent for participating in this clinical\n             trial\n\n          2. Male and Female between 20 and 75 years old\n\n          3. Patients with essential hypertension\n\n          4. Patients who is unresponsive to Fimasartan 60mg monotherapy for 4 weeks (i.e. the\n             mean SiDBP from 3 times of measurement is 140mmHg \u2264 SiSBP <180 mmHg)\n\n          5. Understand the trial procedures and be willing to cooperate and complete the trial.\n\n        Exclusion Criteria:\n\n          1. Severe Hypertension patients (SiDBP \u2265 110mmHg and/or SiSBP \u2265 180mmHg)\n\n          2. Subjects with the difference between blood pressures from a selected arm, SiDBP \u226510\n             mmHg or SiSBP \u226520 mmHg, at screening assessment\n\n          3. Secondary hypertension patients, but not limited to the following disease;(example:\n             renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of\n             the aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis,\n             Cushing's syndrome, pheochromo-cytoma, polycystic kidney disease, etc.)\n\n          4. Clinically significant renal function abnormality in the laboratory results at\n             screening (i.e. serum creatine \u2265 1.5 times upper normal limit (UNL)), liver function\n             abnormality (ALT, AST \u2265 2 times upper normal limit (UNL)), severe fatty liver disease\n             that requires medication\n\n          5. Clinically significant Hypokalemia(Less than 3.5mmol/L), Hyperkalemia(exceeded\n             5.5mmol/L)\n\n          6. Subjects with following surgical and internal disease that may affect absorption,\n             distribution, metabolism or excretion of drugs and have conditions which include the\n             following (but are not limited to): history of major gastrointestinal surgeries\n             including gastrectomy, gastro-enterostomy or bowel resection, gastrointestinal bypass\n             graft and stapling; current active gastritis, ulcer, gastrointestinal and rectal\n             bleeding,  presence of active inflammatory bowel syndrome within the past 12 months;\n             or clinically significant urinary obstruction at discretion of investigator\n\n          7. Subjects with depletion of body fluid or sodium ion not able to correct\n\n          8. Subjects with severe insulin-dependent Diabetes Mellitus (DM) or chronic DM\n             (HbA1c>9%, dosage of an oral hypoglycemic agent was modified within the past 12\n             weeks, or use of active insulin treatment at screening)\n\n          9. Subjects with severe heart disease (heart failure New York Heart Association(NYHA)\n             Class III and IV), or history of any of the followings within the past 6 months;\n             ischemic heart disease(e.g. angina pectoris, myocardial infarction), peripheral\n             vascular disease, percutaneous transluminal coronary angioplasty, or coronary artery\n             bypass graft.\n\n         10. Subjects with clinically significant ventricular tachycardia, atrial fibrillation,\n             atrial flutter or any other clinical significant arrhythmia conditions at discretion\n             of investigator.\n\n         11. Subjects with hypertrophic obstructive cardiomyopathy, severe obstructive coronary\n             artery disease, aortic stenosis, hemodynamically significant aortic valve stenosis,\n             or mitral valve stenosis.\n\n         12. Subjects with severe cerebrovascular disorder (e.g. stroke, cerebral infarction or\n             cerebral hemorrhage within the past 6 months).\n\n         13. Subjects with chronic inflammatory disease requiring an chronic anti-inflammatory\n             therapy, Past or current medical history with wasting disease, autoimmune diseases\n             (e.g. rheumatoid arthritis, systemic lupus erythematosus ) or connective tissue\n             disease.\n\n         14. Subjects with known moderate or malignant retinosis (e.g. retinal hemorrhage, visual\n             disturbance or retinal microaneurysm in the past 6 months).\n\n         15. Subjects with hepatitis B (including positive test for HBsAg), hepatitis C-positive.\n\n         16. Subjects with history or evidence of abusing drugs or alcohol within the past 2\n             years.\n\n         17. Medical history with hypersensitivity to angiotensin II antagonist-based drugs or\n             calcium-channel blockers\n\n         18. Subjects with hereditary disorders of galactose intolerance, Lapp lactase deficiency\n             or glucose-galactose malabsorption\n\n         19. Pregnant women and lactating female\n\n         20. Women of childbearing potential who are not using effective contraceptive methods.\n             (Excluding subjects who had surgically sterilized. All women of childbearing\n             potential who did not have surgical sterilization must prove negative in a pregnancy\n             test, and continue to use accepted and effective contraceptive methods until the end\n             of the study in order to participate. Not accepted contraceptive method: Periodic\n             abstinence and celibacy (e.g. Basic body temperature method, menstrual cycle\n             calculation), hormonal contraceptives.\n\n         21. Subject who is participating in another trial or took other investigational product\n             within12 weeks from the screening visit\n\n         22. Medical history of all kinds of malignant tumor including leukemia and lymphoma in\n             the past 5 years\n\n         23. A subject with other reasons not specified above that, ineligible to participate in\n             this clinical trial at discretion of study investigators."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "140", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 29, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02152306", 
            "org_study_id": "BR-FAC-CT-301"
        }, 
        "intervention": [
            {
                "arm_group_label": "Fimasartan and Amlodipine", 
                "intervention_name": "Fimasartan and Amlodipine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Fimasartan", 
                "intervention_name": "Fimasartan", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Amlodipine"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Fimasartan", 
            "Fimasartan and Amlodipine", 
            "Antihypertension"
        ], 
        "lastchanged_date": "May 29, 2014", 
        "location": {
            "contact": {
                "email": "cheolkim@snu.ac.kr", 
                "last_name": "Cheol Ho Kim, Ph.D.", 
                "phone": "+82-31-787-7001"
            }, 
            "facility": {
                "address": {
                    "city": "Bundang", 
                    "country": "Korea, Republic of", 
                    "state": "Gyeonggi", 
                    "zip": "463-707"
                }, 
                "name": "Seoul National University Bundang Hospital"
            }, 
            "investigator": {
                "last_name": "Cheol Ho Kim, Ph.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Combination of Fimasartan/Amlodipine Versus Fimasartan Monotherapy in Patients With Essential Hypertension Who Fail to Respond Adequately to Fimasartan Monotherapy.", 
        "other_outcome": [
            {
                "measure": "Adverse Events", 
                "safety_issue": "No", 
                "time_frame": "12 weeks from Screening Visit"
            }, 
            {
                "measure": "Adverse Changes in Laboratory Test Results", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks from Screening Visit"
            }, 
            {
                "measure": "Adverse Changes in Electrocardiography (ECG)", 
                "safety_issue": "Yes", 
                "time_frame": "12 weeks from Screening Visit"
            }
        ], 
        "overall_contact": {
            "email": "kminlee@boryung.co.kr", 
            "last_name": "Minlee Kim", 
            "phone": "+82-2-708-8065"
        }, 
        "overall_contact_backup": {
            "email": "sehan83@boryung.co.kr", 
            "last_name": "Su-Eun Han, Ph.D.", 
            "phone": "+82-2-708-8163"
        }, 
        "overall_official": {
            "affiliation": "Seoul National University Bundang Hospital", 
            "last_name": "Cheol Ho Kim, Ph.D.", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "South Korea: Ministy of Food and Drug Safety", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To compare the difference of Mean Systolic Blood Pressure at 8 weeks from baseline visit", 
            "measure": "Change of Sitting Systolic Blood Pressure(SiSBP) at week 8 of Investigational Product(IP) Administration from the Baseline", 
            "safety_issue": "No", 
            "time_frame": "8 weeks from Baseline Visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02152306"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change of Sitting Systolic Blood Pressure(SiSBP) at week 4 of Investigational Product(IP) Administration from the Baseline", 
                "safety_issue": "No", 
                "time_frame": "4 weeks from Baseline Visit"
            }, 
            {
                "measure": "Changes of Sitting Diastolic Blood Pressure(SiDBP) at week 4 and 8 of Investigational Product(IP) Administration from the Baseline", 
                "safety_issue": "No", 
                "time_frame": "4 and 8 weeks from Baseline Visit"
            }, 
            {
                "measure": "Response rate of the Blood Pressure at week 8 of Investigational Product(IP) Administration", 
                "safety_issue": "No", 
                "time_frame": "8 weeks from Baseline Visit"
            }, 
            {
                "measure": "The Normalization ratio of Blood Pressure at week 8 of Investigational Product(IP) Administration", 
                "safety_issue": "No", 
                "time_frame": "8 weeks from Baseline Visit"
            }
        ], 
        "source": "Boryung Pharmaceutical Co., Ltd", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Gachon University Gil Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Catholic University of Korea Bucheon St.Mary's Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "The Catholic University of Korea", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Kangbuk Samsung Medical center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Kyungbook National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Keimyung University Dongsan Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Korea University Guro Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Korea University Anam Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "DongGuk University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Dong-A University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Busan University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Seoul National University Bundang Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Seoul National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Asan Medical Center", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Busan university Yangsan Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Wonju Severance Christian Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Gangnam Severance Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Severance Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Ulsan University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Inje University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Inje University Haeundai Paik Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chonnam National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Jeju National University Hospital", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Chungnam National University", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hanyang University Seoul Hoapital", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Boryung Pharmaceutical Co., Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}